<!DOCTYPE html>
<html lang="tr">
<head>
<link rel="alternate" hreflang="tr" href="https://uzunyasa.com/pages/blog/glp1-ilaclari-kanser-riskini-artirir-mi-guncel-bilimsel-veri.html">
<link rel="alternate" hreflang="x-default" href="https://uzunyasa.com/pages/blog/glp1-ilaclari-kanser-riskini-artirir-mi-guncel-bilimsel-veri.html">
<meta http-equiv="Content-Language" content="tr">
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>GLP-1 Ä°laÃ§larÄ± Kanser Riskini ArtÄ±rÄ±r mÄ±? GÃ¼ncel Bilimsel Veriler | UzunYaÅŸa Blog</title>
    <meta name="description" content="GLP-1 reseptÃ¶r agonistlerinin kanser riskine etkisi hakkÄ±nda 2025'in en gÃ¼ncel meta-analiz bulgularÄ±nÄ± inceleyen kapsamlÄ± deÄŸerlendirme.">
    <link rel="canonical" href="https://uzunyasa.com/pages/blog/glp1-ilaclari-kanser-riskini-artirir-mi-guncel-bilimsel-veri.html">
    <meta property="og:title" content="GLP-1 Ä°laÃ§larÄ± Kanser Riskini ArtÄ±rÄ±r mÄ±? GÃ¼ncel Bilimsel Veriler">
    <meta property="og:description" content="GLP-1 reseptÃ¶r agonistlerinin kanser riskine etkisi hakkÄ±nda 2025'in en gÃ¼ncel meta-analiz bulgularÄ±nÄ± inceleyen kapsamlÄ± deÄŸerlendirme.">
    <meta property="og:image" content="https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=1200&h=600&fit=crop">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://uzunyasa.com/pages/blog/glp1-ilaclari-kanser-riskini-artirir-mi-guncel-bilimsel-veri.html">
    <meta property="og:site_name" content="UzunYaÅŸa">
    <meta property="article:published_time" content="2026-02-23">
    <meta property="article:section" content="Tedavi">
    <meta property="article:tag" content="glp-1">
    <meta property="article:tag" content="kanser-riski">
    <meta property="article:tag" content="diyabet">
    <meta property="article:tag" content="obezite">
    <meta property="article:tag" content="semaglutid">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="GLP-1 Ä°laÃ§larÄ± Kanser Riskini ArtÄ±rÄ±r mÄ±? GÃ¼ncel Bilimsel Veriler">
    <meta name="twitter:description" content="GLP-1 reseptÃ¶r agonistlerinin kanser riskine etkisi hakkÄ±nda 2025'in en gÃ¼ncel meta-analiz bulgularÄ±nÄ± inceleyen kapsamlÄ± deÄŸerlendirme.">
    <meta name="twitter:image" content="https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=1200&h=600&fit=crop">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <!-- Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
    <script>window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments);}gtag('js',new Date());gtag('config','G-QBM7E0EHFP');</script>
    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@type": "Article",
      "headline": "GLP-1 Ä°laÃ§larÄ± Kanser Riskini ArtÄ±rÄ±r mÄ±? GÃ¼ncel Bilimsel Veriler",
      "description": "GLP-1 reseptÃ¶r agonistlerinin kanser riskine etkisi hakkÄ±nda 2025'in en gÃ¼ncel meta-analiz bulgularÄ±nÄ± inceleyen kapsamlÄ± deÄŸerlendirme.",
      "image": "https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=1200&h=600&fit=crop",
      "datePublished": "2026-02-23",
      "author": {
        "@type": "Organization",
        "name": "UzunYaÅŸa",
        "url": "https://uzunyasa.com"
      },
      "publisher": {
        "@type": "Organization",
        "name": "UzunYaÅŸa",
        "logo": { "@type": "ImageObject", "url": "https://uzunyasa.com/images/logo.svg" }
      },
      "mainEntityOfPage": "https://uzunyasa.com/pages/blog/glp1-ilaclari-kanser-riskini-artirir-mi-guncel-bilimsel-veri.html"
    }
    </script>
    <style>
        :root {
            --primary: #195157;
            --accent: #E8963E;
            --text: #1a1a1a;
            --gray: #6b7280;
            --bg: #FAF9F7;
            --white: #FFFFFF;
            --border: #e5e7eb;
            --category-color: #EC4899;
        }
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: 'Inter', sans-serif; color: var(--text); line-height: 1.8; background: var(--bg); }
        .header { position: fixed; top: 0; left: 0; right: 0; z-index: 1000; background: rgba(255,255,255,0.97); backdrop-filter: blur(10px); border-bottom: 1px solid var(--border); }
        .header-inner { max-width: 1200px; margin: 0 auto; padding: 0.75rem 2rem; display: flex; align-items: center; justify-content: space-between; }
        .logo-img { height: 60px; }
        .back-link { color: var(--primary); text-decoration: none; font-weight: 500; }
        .back-link:hover { text-decoration: underline; }
        article { max-width: 750px; margin: 0 auto; padding: 7rem 1.5rem 4rem; }
        .post-category { display: inline-block; background: #EC489920; color: #EC4899; padding: 0.4rem 1rem; border-radius: 20px; font-size: 0.85rem; font-weight: 600; margin-bottom: 1rem; }
        h1 { font-size: 2.25rem; font-weight: 700; line-height: 1.3; margin-bottom: 1rem; }
        .post-meta { color: var(--gray); font-size: 0.9rem; display: flex; gap: 1rem; flex-wrap: wrap; margin-bottom: 2rem; }
        .featured-image { width: 100%; height: 350px; border-radius: 16px; overflow: hidden; margin-bottom: 2.5rem; }
        .featured-image img { width: 100%; height: 100%; object-fit: cover; }
        .post-content { font-size: 1.1rem; }
        .post-content h2 { font-size: 1.5rem; margin: 2.5rem 0 1rem; color: var(--primary); }
        .post-content h3 { font-size: 1.25rem; margin: 2rem 0 0.75rem; }
        .post-content p { margin-bottom: 1.25rem; }
        .post-content ul, .post-content ol { margin: 1rem 0 1.5rem 1.5rem; }
        .post-content li { margin-bottom: 0.5rem; }
        .post-content blockquote { border-left: 4px solid var(--accent); padding-left: 1.5rem; margin: 1.5rem 0; font-style: italic; color: var(--gray); }
        .post-content strong { color: var(--primary); }
        .key-points { background: var(--white); border: 2px solid var(--border); border-radius: 12px; padding: 1.5rem 1.5rem 1.5rem 2rem; margin: 2.5rem 0; }
        .key-points h4 { color: var(--primary); margin-bottom: 1rem; font-size: 1.1rem; }
        .key-points ul { margin: 0; }
        .key-points li { margin-bottom: 0.5rem; }
        .sources { margin-top: 3rem; padding-top: 2rem; border-top: 1px solid var(--border); }
        .sources h4 { font-size: 1rem; margin-bottom: 0.75rem; color: var(--primary); }
        .sources ul { list-style: none; margin: 0; padding: 0; }
        .sources li { font-size: 0.9rem; color: var(--gray); margin-bottom: 0.5rem; }
        .sources a { color: var(--primary); }
        .disclaimer { background: #FEF3C7; border: 1px solid #F59E0B; border-radius: 8px; padding: 1rem; margin-top: 2rem; font-size: 0.9rem; color: #92400E; }
        .share-section { margin-top: 3rem; padding: 2rem; background: var(--white); border-radius: 12px; text-align: center; border: 1px solid var(--border); }
        .share-buttons { display: flex; gap: 0.75rem; justify-content: center; margin-top: 1rem; flex-wrap: wrap; }
        .share-btn { padding: 0.65rem 1.25rem; border-radius: 8px; text-decoration: none; font-weight: 500; font-size: 0.9rem; color: white; }
        .share-btn.twitter { background: #1DA1F2; }
        .share-btn.linkedin { background: #0A66C2; }
        .share-btn.whatsapp { background: #25D366; }
        .cta-section { margin-top: 3rem; padding: 2rem; background: linear-gradient(135deg, var(--primary), #2a6b73); border-radius: 12px; text-align: center; color: white; }
        .cta-section h3 { margin-bottom: 0.5rem; }
        .cta-section p { opacity: 0.9; margin-bottom: 1rem; }
        .cta-btn { display: inline-block; background: var(--accent); color: white; padding: 0.875rem 2rem; border-radius: 8px; text-decoration: none; font-weight: 600; }
        footer { background: var(--text); color: white; padding: 2rem; text-align: center; margin-top: 4rem; }
        footer p { opacity: 0.7; font-size: 0.9rem; }
        @media (max-width: 640px) { h1 { font-size: 1.65rem; } article { padding: 5.5rem 1rem 2rem; } .featured-image { height: 220px; } }
    </style>
</head>
<body>
    <header class="header">
        <div class="header-inner">
            <a href="../../index.html"><img src="../../images/logo.svg" alt="UzunYaÅŸa" class="logo-img"></a>
            <a href="../blog.html" class="back-link">â† Blog'a DÃ¶n</a>
        </div>
    </header>

    <article>
        <span class="post-category">ğŸ’Š Tedavi</span>
        <h1>GLP-1 Ä°laÃ§larÄ± Kanser Riskini ArtÄ±rÄ±r mÄ±? GÃ¼ncel Bilimsel Veriler</h1>
        <div class="post-meta">
            <span>ğŸ“… 23 Åubat 2026</span>
            <span>â±ï¸ 10 dk okuma</span>
            <span>ğŸ“Š KanÄ±ta DayalÄ±</span>
        </div>

        <div class="featured-image">
            <img src="https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=1200&h=600&fit=crop" alt="GLP-1 Ä°laÃ§larÄ± Kanser Riskini ArtÄ±rÄ±r mÄ±? GÃ¼ncel Bilimsel Veriler" loading="lazy">
        </div>

        <div class="post-content">
            <p>Son yÄ±llarda diyabet ve obezite tedavisinde yaygÄ±nlaÅŸan GLP-1 reseptÃ¶r agonistleri (semaglutid/Ozempic, liraglutid gibi) milyonlarca kiÅŸi tarafÄ±ndan kullanÄ±lÄ±yor. Ancak bu ilaÃ§larÄ±n uzun vadeli gÃ¼venliÄŸi, Ã¶zellikle kanser riski konusunda endiÅŸeler var mÄ±ydÄ±? 2025'te yayÄ±nlanan iki bÃ¼yÃ¼k meta-analiz bu soruya net cevaplar veriyor.</p><h2>GLP-1 Ä°laÃ§larÄ± Nedir ve Neden KullanÄ±lÄ±r?</h2><p>GLP-1 reseptÃ¶r agonistleri, vÃ¼cudun doÄŸal hormon sistemini taklit eden ilaÃ§lardÄ±r. <strong>Ä°nkretin hormonlarÄ±</strong> adÄ± verilen bu sistem:</p>
<ul><li>Ä°nsÃ¼lin salgÄ±sÄ±nÄ± artÄ±rÄ±r (sadece kan ÅŸekeri yÃ¼ksekken)</li>
<li>Glukagon hormonunu baskÄ±lar</li>
<li>Mide boÅŸalmasÄ±nÄ± yavaÅŸlatÄ±r</li>
<li><strong>Tokluk hissini</strong> gÃ¼Ã§lendirir</li>
</ul>
<p>Bu Ã¶zellikler sayesinde hem tip 2 diyabet hem de obezite tedavisinde kullanÄ±lÄ±yorlar. TÃ¼rkiye'de SGK kapsamÄ±nda diyabet hastalarÄ±na, Ã¶zel koÅŸullarda da obezite tedavisinde reÃ§ete edilebiliyorlar.</p><h2>BÃ¼yÃ¼k Meta-Analizlerden Ne Ã–ÄŸrendik?</h2><h3>ğŸŸ¢ Ä°lk Ã‡alÄ±ÅŸma: 4 Milyona YakÄ±n Hasta Verisi</h3><p><strong>Ateiwi ve arkadaÅŸlarÄ±nÄ±n</strong> 2026'da yayÄ±nlanan Ã§alÄ±ÅŸmasÄ±, ÅŸimdiye kadarki en kapsamlÄ± analizlerden biri. <strong>3.960.974 hasta</strong> verisi incelendi ve sonuÃ§lar dikkat Ã§ekici:</p><p><strong>Ana bulgular:</strong></p>
<ul><li><strong>Genel obezite iliÅŸkili kanser riski %30 azaldÄ±</strong> (RR 0.70, %95 CI 0.54-0.89)</li>
<li>Ã–zellikle azalan kanser tÃ¼rleri:</li>
</ul>  - KaraciÄŸer kanseri (hepatoselÃ¼ler karsinom)</p>
<p>  - Kolorektal kanser</p>
<p>  - Pankreas kanseri</p>
<p>  - Endometrium (rahim) kanseri</p>
<p>  - Ã–zofagus (yemek borusu) kanseri</p>
<p>  - Safra kesesi kanseri</p>
<p>  - Over kanseri</p>
<p>  - Multiple myeloma</p><h3>ğŸŸ¢ Ä°kinci Ã‡alÄ±ÅŸma: Randomize KontrollÃ¼ Ã‡alÄ±ÅŸmalar</h3><p><strong>Ko ve arkadaÅŸlarÄ±nÄ±n</strong> meta-analizi, <strong>48 randomize kontrollÃ¼ Ã§alÄ±ÅŸma</strong>dan 94.245 katÄ±lÄ±mcÄ± verisi analiz etti. Bu Ã§alÄ±ÅŸmanÄ±n Ã¶nemli yanÄ±, sadece "altÄ±n standart" olan RKÃ‡'larÄ± dahil etmesi:</p><p><strong>Temel sonuÃ§lar:</strong></p>
<ul><li><strong>Tiroid kanseri</strong>: ArtÄ±ÅŸ yok (OR 1.37, anlamlÄ± deÄŸil)</li>
<li><strong>Pankreas kanseri</strong>: Risk deÄŸiÅŸmedi (OR 0.84)</li>
<li><strong>Meme kanseri</strong>: NÃ¶tr etki (OR 0.95)</li>
<li><strong>BÃ¶brek kanseri</strong>: Risk artÄ±ÅŸÄ± gÃ¶rÃ¼lmedi (OR 1.12)</li>
</ul>
<h3>Bu AraÅŸtÄ±rmalar Ne Anlama Geliyor?</h3></p><p>1. <strong>Koruyucu etki var</strong>: Obezite ile iliÅŸkili birÃ§ok kanser tÃ¼rÃ¼nde risk azalÄ±yor
<p>2. <strong>Zarar vermiyor</strong>: HiÃ§bir kanser tÃ¼rÃ¼nde anlamlÄ± risk artÄ±ÅŸÄ± yok</p>
<p>3. <strong>Tiroid kanseri korkusu gereksiz</strong>: En Ã§ok endiÅŸe duyulan bu konuda da problem gÃ¶rÃ¼lmÃ¼yor</p><h2>Neden Bu Koruyucu Etki Oluyor?</h2><h3>OlasÄ± Mekanizmalar:</h3><p><strong>1. Kilo KaybÄ± Etkisi</strong></p>
<ul><li>Obezite, 13 farklÄ± kanser tÃ¼rÃ¼ iÃ§in risk faktÃ¶rÃ¼</li>
<li><a href="glp1-tam-rehber.html" style="color:#0D7377; text-decoration:underline; text-decoration-color:rgba(13,115,119,0.3); text-underline-offset:2px;">GLP-1 ilaÃ§larÄ±</a> ile %10-15 kilo kaybÄ± saÄŸlanÄ±yor</li>
<li>Kilo kaybÄ± â†’ hormon dengesi iyileÅŸiyor â†’ kanser riski azalÄ±yor</li>
</ul>
<p><strong>2. Ä°nsÃ¼lin Direnci Ä°yileÅŸmesi</strong></p>
<ul><li>YÃ¼ksek insÃ¼lin seviyeleri bÃ¼yÃ¼me faktÃ¶rlerini uyarÄ±r</li>
<li>GLP-1 ilaÃ§larÄ± insÃ¼lin duyarlÄ±lÄ±ÄŸÄ±nÄ± artÄ±rÄ±r</li>
<li>Daha dÃ¼ÅŸÃ¼k insÃ¼lin â†’ daha az tÃ¼mÃ¶r bÃ¼yÃ¼mesi</li>
</ul>
<p><strong>3. Ä°nflamasyonun AzalmasÄ±</strong></p>
<ul><li>Kronik inflamasyon kanser geliÅŸimini hÄ±zlandÄ±rÄ±r</li>
<li>Bu ilaÃ§lar anti-inflamatuar etki gÃ¶sterir</li>
<li>Daha az inflamasyon â†’ daha az kanser riski</li>
</ul>
<p><strong>4. Metabolik SaÄŸlÄ±ÄŸÄ±n Ä°yileÅŸmesi</strong></p>
<ul><li>Kan ÅŸekeri kontrolÃ¼ â†’ daha az DNA hasarÄ±</li>
<li>Lipid profilinde iyileÅŸme â†’ hÃ¼cresel saÄŸlÄ±k artÄ±ÅŸÄ±</li>
</ul>
<h2>TÃ¼rkiye'deki Durum: Pratik Bilgiler</h2></p><h3>SGK KapsamÄ±:</h3>
<ul><li><strong>Tip 2 diyabet</strong>: Metformin + baÅŸka bir ilaÃ§la kontrol saÄŸlanamayÄ±nca</li>
<li><strong>Obezite</strong>: HenÃ¼z rutin SGK kapsamÄ±nda deÄŸil, Ã¶zel koÅŸullarda onay alÄ±nabiliyor</li>
<li><strong>Ã–zel sigorta</strong>: BazÄ± firmalar karÅŸÄ±lÄ±yor, kontrol etmekte fayda var</li>
</ul>
<h3>Maliyetler (2025 tahmini):</h3>
<ul><li>AylÄ±k maliyet: 800-2000 TL arasÄ± (ilaca gÃ¶re deÄŸiÅŸiyor)</li>
<li>Uzun vadeli kullanÄ±m gerekiyor</li>
<li>Kilo kaybÄ± sonrasÄ± doz azaltÄ±labiliyor</li>
</ul>
<h3>Hangi Doktor Yazabilir?</h3>
<ul><li><strong>Endokrinoloji uzmanlarÄ±</strong> (birinci terciH)</li>
<li><strong>Ä°Ã§ hastalÄ±klarÄ± uzmanlarÄ±</strong></li>
<li><strong>Aile hekimleri</strong> (belirli koÅŸullarda)</li>
</ul>
<h2>Bu SonuÃ§lar GÃ¼nlÃ¼k Hayatta Ne Anlama Geliyor?</h2></p><h3>EÄŸer Åu Anda KullanÄ±yorsanÄ±z:</h3><p>âœ… <strong>Rahat olun</strong>: Kanser riski konusunda endiÅŸelenmenize gerek yok
<p>âœ… <strong>Devam edin</strong>: Hekiminizin Ã¶nerdiÄŸi ÅŸekilde kullanmaya devam edin</p>
<p>âœ… <strong>DÃ¼zenli takip</strong>: Rutin kontrollerinizi aksatmayÄ±n</p><h3>EÄŸer DÃ¼ÅŸÃ¼nÃ¼yorsanÄ±z:</h3><p>ğŸ¤” <strong>EndikasyonlarÄ±nÄ±zÄ± deÄŸerlendirin</strong>:</p>
<ul><li>BMI >30 veya BMI >27 + diyabet/hipertansiyon</li>
<li>Tip 2 diyabet + yetersiz kontrol</li>
<li>KardiyovaskÃ¼ler risk yÃ¼ksekliÄŸi</li>
</ul>
<p>ğŸ¤” <strong>Maliyet-fayda analizi yapÄ±n</strong>:</p>
<ul><li>AylÄ±k maliyet vs. saÄŸlÄ±k yararlarÄ±</li>
<li>Uzun vadeli kullanÄ±m gerekliliÄŸi</li>
<li>DiÄŸer tedavi seÃ§enekleriyle karÅŸÄ±laÅŸtÄ±rma</li>
</ul>
<h3>YaÅŸam TarzÄ± Ã–nlemleri UnutmayÄ±n!</h3></p><p>GLP-1 ilaÃ§larÄ± tek baÅŸÄ±na yeterli deÄŸil. En iyi sonuÃ§ iÃ§in:
<ul><li><strong>Dengeli beslenme</strong> devam etmeli</li>
<li><strong>DÃ¼zenli egzersiz</strong> ÅŸart</li>
<li><strong>Stres yÃ¶netimi</strong> Ã¶nemli</li>
<li><strong>Uyku kalitesi</strong> ihmal edilmemeli</li>
</ul>
<h2>Gelecekte Neler Bekleyebiliriz?</h2></p><h3>AraÅŸtÄ±rma AlanlarÄ±:</h3>
<ul><li>Daha uzun sÃ¼reli takip Ã§alÄ±ÅŸmalarÄ±</li>
<li>FarklÄ± kanser tÃ¼rlerinde spesifik etkiler</li>
<li>Optimal doz ve sÃ¼re araÅŸtÄ±rmalarÄ±</li>
<li>TÃ¼rkiye'ye Ã¶zgÃ¼ kohort Ã§alÄ±ÅŸmalarÄ±</li>
</ul>
<h3>EriÅŸim Ä°yileÅŸtirmeleri:</h3>
<ul><li>SGK kapsamÄ±nÄ±n geniÅŸlemesi bekleniyor</li>
<li>Biosimilar (biyobenzer) ilaÃ§lar geliÅŸtirilmekte</li>
<li>Maliyet azalmasÄ± Ã¶ngÃ¶rÃ¼lÃ¼yor</li>
</ul>
<h2>Ã–nemli UyarÄ±lar ve SÄ±nÄ±rlamalar</h2></p><h3>ğŸ” Bu SonuÃ§larÄ±n SÄ±nÄ±rlarÄ±:</h3>
<ul><li>Ã‡oÄŸu Ã§alÄ±ÅŸma 10 yÄ±ldan kÄ±sa takip sÃ¼reli</li>
<li>Kanser geliÅŸimi uzun yÄ±llar alabiliyor</li>
<li>FarklÄ± kanser tÃ¼rleri iÃ§in ayrÄ± analizler gerekli</li>
<li>Genetik faktÃ¶rler hesaba katÄ±lmamÄ±ÅŸ</li>
</ul>
<h3>âš ï¸ Dikkat Edilmesi Gerekenler:</h3>
<ul><li><strong>Hamilelik</strong>: GÃ¼venlik verisi yetersiz</li>
<li><strong>Aile kanseri Ã¶ykÃ¼sÃ¼</strong>: Ekstra dikkat gerekebilir</li>
<li><strong>Aktif kanser tedavisi</strong>: Onkolog ile koordinasyon ÅŸart</li>
<li><strong>DiÄŸer ilaÃ§ etkileÅŸimleri</strong>: Tam liste hekime verilmeli</li>
</ul>
<h2>SonuÃ§: Bilimsel Veriler Ne Diyor?</h2></p><p>Ä°ki bÃ¼yÃ¼k meta-analizin verdiÄŸi mesaj aÃ§Ä±k: <strong>GLP-1 reseptÃ¶r agonistleri kanser riski artÄ±rmÄ±yor, hatta birÃ§ok kanser tÃ¼rÃ¼ iÃ§in koruyucu etki gÃ¶sterebiliyor</strong>. Bu, Ã¶zellikle obezite ve diyabet hastalarÄ±nda Ã§ok deÄŸerli bir bulgu.</p><p>Ancak unutmayÄ±n: <strong>Her hasta farklÄ±, her durum Ã¶zel</strong>. Bu ilaÃ§lar hakkÄ±ndaki kararÄ± mutlaka uzman hekiminizle birlikte verin. Kendi saÄŸlÄ±k durumunuz, risk faktÃ¶rleriniz ve ekonomik durumunuz dikkate alÄ±narak en doÄŸru karar verilecektir.</p><p><strong>Temel mesaj</strong>: GLP-1 ilaÃ§larÄ±nÄ±n kanser riski konusundaki endiÅŸeler bilimsel verilerle desteklenmiyor. Aksine, obezite ile mÃ¼cadelede gÃ¼venli ve etkili bir seÃ§enek olduklarÄ±nÄ± gÃ¶steren gÃ¼Ã§lÃ¼ kanÄ±tlar var.</p><p>---</p><p><em>Bu makale Prof. Dr. Cem ÅimÅŸek editÃ¶rlÃ¼ÄŸÃ¼nde, gÃ¼ncel bilimsel literatÃ¼r temel alÄ±narak hazÄ±rlanmÄ±ÅŸtÄ±r. KiÅŸisel saÄŸlÄ±k kararlarÄ±nÄ±z iÃ§in mutlaka hekiminize danÄ±ÅŸÄ±n.</em>
        </div>

        <div class="key-points">
            <h4>ğŸ“Œ Ã–nemli Noktalar</h4>
            <ul><li>4 milyona yakÄ±n hasta verisi GLP-1 ilaÃ§larÄ±nÄ±n kanser riskini %30 azalttÄ±ÄŸÄ±nÄ± gÃ¶steriyor</li>
<li>En Ã§ok endiÅŸe duyulan tiroid kanseri dahil hiÃ§bir kanser tÃ¼rÃ¼nde risk artÄ±ÅŸÄ± gÃ¶rÃ¼lmÃ¼yor</li>
<li>KaraciÄŸer, kolorektal, pankreas ve endometrium kanserlerinde belirgin koruyucu etki var</li>
<li>Kilo kaybÄ±, <a href="insulin-direnci-belirtiler-tedavi.html" style="color:#0D7377; text-decoration:underline; text-decoration-color:rgba(13,115,119,0.3); text-underline-offset:2px;">insÃ¼lin direnci</a> iyileÅŸmesi ve inflamasyonun azalmasÄ± koruyucu mekanizmalar</li></ul>
        </div>

        <div class="disclaimer">
            âš ï¸ <strong>Ã–nemli:</strong> Bu iÃ§erik sadece bilgilendirme amaÃ§lÄ±dÄ±r ve tÄ±bbi tavsiye yerine geÃ§mez. Herhangi bir tedaviye baÅŸlamadan Ã¶nce mutlaka doktorunuza danÄ±ÅŸÄ±n.
        </div>

        <div class="sources">
            <h4>ğŸ“š Kaynaklar</h4>
            <ul><li><a href="https://doi.org/10.1016/j.diabres.2026.113158" target="_blank" rel="noopener">Ateiwi YA, et al. Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026;113158</a></li>
<li><a href="https://doi.org/10.7326/ANNALS-25-02237" target="_blank" rel="noopener">Ko A, et al. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis. Ann Intern Med. 2026</a></li></ul>
        </div>

        <div class="share-section">
            <p><strong>Bu yazÄ±yÄ± paylaÅŸÄ±n</strong></p>
            <div class="share-buttons">
                <a href="https://twitter.com/intent/tweet?text=GLP-1%20%C4%B0la%C3%A7lar%C4%B1%20Kanser%20Riskini%20Art%C4%B1r%C4%B1r%20m%C4%B1%3F%20G%C3%BCncel%20Bilimsel%20Veriler%20%7C%20UzunYa%C5%9Fa&url=https%3A%2F%2Fuzunyasa.com%2Fpages%2Fblog%2Fglp1-ilaclari-kanser-riskini-artirir-mi-guncel-bilimsel-veri.html" class="share-btn twitter" target="_blank" rel="noopener">Twitter</a>
                <a href="https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fuzunyasa.com%2Fpages%2Fblog%2Fglp1-ilaclari-kanser-riskini-artirir-mi-guncel-bilimsel-veri.html" class="share-btn linkedin" target="_blank" rel="noopener">LinkedIn</a>
                <a href="https://wa.me/?text=GLP-1%20%C4%B0la%C3%A7lar%C4%B1%20Kanser%20Riskini%20Art%C4%B1r%C4%B1r%20m%C4%B1%3F%20G%C3%BCncel%20Bilimsel%20Veriler%20https%3A%2F%2Fuzunyasa.com%2Fpages%2Fblog%2Fglp1-ilaclari-kanser-riskini-artirir-mi-guncel-bilimsel-veri.html" class="share-btn whatsapp" target="_blank" rel="noopener">WhatsApp</a>
            </div>
        </div>

        

<!-- Ä°LGÄ°LÄ° YAZILAR - Auto-generated by internal-links.js -->
<div class="related-posts-section" style="margin-top:3rem; padding-top:2rem; border-top:2px solid #e5e7eb;">
  <div style="display:flex; align-items:center; gap:12px; margin-bottom:1.5rem;">
    <div style="width:4px; height:32px; background:linear-gradient(to bottom, #0D7377, #14919B); border-radius:2px;"></div>
    <h2 style="margin:0; font-family:'Playfair Display', serif; font-size:1.5rem; color:#195157;">Ä°lgili YazÄ±lar</h2>
  </div>
  <div style="display:flex; flex-wrap:wrap; gap:1rem;">

      <a href="ramazanda-glp1-kullananlar-icin-oruc-rehberi.html" class="related-post-card" style="text-decoration:none; color:inherit; display:block; background:#fff; border:1px solid #e5e7eb; border-radius:12px; padding:1.25rem; transition:all 0.2s ease; flex:1; min-width:250px;">
        <div style="display:flex; align-items:center; gap:8px; margin-bottom:0.75rem;">
          <span style="font-size:1.2rem;">ğŸ’Š</span>
          <span style="font-size:0.75rem; font-weight:600; color:#EC4899; text-transform:uppercase; letter-spacing:0.5px;">Tedavi</span>
        </div>
        <h4 style="font-size:0.95rem; font-weight:600; color:#195157; margin-bottom:0.5rem; line-height:1.4;">Ramazanda GLP-1 Kullananlar Ä°Ã§in OruÃ§ Rehberi</h4>
        <p style="font-size:0.85rem; color:#6B7280; line-height:1.5; margin:0;">GLP-1 ilaÃ§larÄ±yla Ramazan orucunu gÃ¼venle tutmanÄ±n bilimsel rehberi. Ä°laÃ§ zamanlamasÄ±, hipoglisemi Ã¶nlemi, protein hedefâ€¦</p>
      </a>

      <a href="semaglutid-ve-pankreatit-riski-vaka-raporlari-isiginda-guven.html" class="related-post-card" style="text-decoration:none; color:inherit; display:block; background:#fff; border:1px solid #e5e7eb; border-radius:12px; padding:1.25rem; transition:all 0.2s ease; flex:1; min-width:250px;">
        <div style="display:flex; align-items:center; gap:8px; margin-bottom:0.75rem;">
          <span style="font-size:1.2rem;">ğŸ’Š</span>
          <span style="font-size:0.75rem; font-weight:600; color:#EC4899; text-transform:uppercase; letter-spacing:0.5px;">Tedavi</span>
        </div>
        <h4 style="font-size:0.95rem; font-weight:600; color:#195157; margin-bottom:0.5rem; line-height:1.4;">Semaglutid ve Pankreatit Riski: Vaka RaporlarÄ± IÅŸÄ±ÄŸÄ±nda GÃ¼venlik</h4>
        <p style="font-size:0.85rem; color:#6B7280; line-height:1.5; margin:0;">Semaglutid kullanÄ±mÄ± sÄ±rasÄ±nda akut pankreatit riski ve gÃ¼venlik Ã¶nlemleri. GÃ¼ncel vaka raporlarÄ± ve araÅŸtÄ±rma bulgularÄ±â€¦</p>
      </a>

      <a href="tirzepatide-yeni-nesil-kilo-verme-ilacinin-bilimsel-gercekle.html" class="related-post-card" style="text-decoration:none; color:inherit; display:block; background:#fff; border:1px solid #e5e7eb; border-radius:12px; padding:1.25rem; transition:all 0.2s ease; flex:1; min-width:250px;">
        <div style="display:flex; align-items:center; gap:8px; margin-bottom:0.75rem;">
          <span style="font-size:1.2rem;">ğŸ’Š</span>
          <span style="font-size:0.75rem; font-weight:600; color:#EC4899; text-transform:uppercase; letter-spacing:0.5px;">Tedavi</span>
        </div>
        <h4 style="font-size:0.95rem; font-weight:600; color:#195157; margin-bottom:0.5rem; line-height:1.4;">Tirzepatide: Yeni Nesil Kilo Verme Ä°lacÄ±nÄ±n Bilimsel GerÃ§ekleri</h4>
        <p style="font-size:0.85rem; color:#6B7280; line-height:1.5; margin:0;">Tirzepatide (Mounjaro/Zepbound) ile ilgili gÃ¼ncel araÅŸtÄ±rmalar, etkinlik oranlarÄ± ve TÃ¼rkiye'deki durum hakkÄ±nda kapsamlâ€¦</p>
      </a>
  </div>
  <style>
    .related-post-card:hover { transform:translateY(-2px); box-shadow:0 4px 12px rgba(0,0,0,0.1); border-color:#14919B !important; }
    @media(max-width:768px) { .related-post-card { min-width:100% !important; } }
  </style>
</div>
<!-- END Ä°LGÄ°LÄ° YAZILAR -->

<div class="cta-section">
            <h3>SaÄŸlÄ±ÄŸÄ±nÄ±zÄ± test edin</h3>
            <p>2 dakikada kiÅŸisel saÄŸlÄ±k deÄŸerlendirmenizi yapÄ±n</p>
            <a href="../test.html" class="cta-btn">Teste BaÅŸla â†’</a>
        </div>
    </article>

    <footer><p>Â© 2026 UzunYaÅŸa. TÃ¼m haklarÄ± saklÄ±dÄ±r.</p></footer>
<script src="/scripts/premium-animations.js" defer></script>
</body>
</html>